Endo International (NASDAQ:ENDP) subsidiary, Par Sterile Products enters into a non-exclusive agreement with Novavax (NASDAQ:NVAX) to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax' COVID-19 vaccine candidate.
The Rochester facility has begun production of NVX-CoV2373 final drug product, with initial batches to be used in Novavax' pivotal Phase 3 clinical trial in the US.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.